Physician profile
Simran Arora
NPI 1578976791
$998.08
in general payments reported to CMS, 2019-2025
15 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.86 · 2022: $134 · 2023: $86.96 · 2024: $425 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $220.05 | 2023-2025 | |
| Abbvie INC. | $139.52 | 2022-2024 | Linzess, Viberzi |
| Otsuka America Pharmaceutical, INC. | $139.07 | 2024-2025 | Rexulti |
| Ethicon INC. | $118.15 | 2022 | |
| Lilly USA, LLC | $85.75 | 2024-2025 | Mounjaro, Zepbound |
| Lundbeck LLC | $70.11 | 2023-2024 | Rexulti |
| Novo Nordisk INC | $63.19 | 2023-2024 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $47.51 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $23.51 | 2024 | Voquezna |
| Amgen INC. | $19.82 | 2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $17.77 | 2024 | |
| Shire North American Group INC | $14.53 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.77 | 2024 | Airsupra |
| Janssen Pharmaceuticals, INC | $12.97 | 2019 | |
| Assertio Therapeutics, INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simran Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.